Interference of ANTIBACTERIAL AGENTS with the immune system, and its possible clinical implications, have long been a focus of attention worldwide. Toxic effects with immunological implications (neutropenia, ALLERGY, etc.) influenced the therapeutic choice early in the antimicrobial era, but attention has gradually shifted to beneficial "IMMUNOMODULATORY"properties. Many papers in this field have been published and periodically reviewed over the last three decades [1][2][3][4][5][6][7][8][9]. Interest in "immunostimulation" peaked in the 1970s. Only recently have the potential benefits of down-regulating immune effectors come into the limelight,with the understanding that immune hyperactivation (in sepsis and inflammatory/AUTOIMMUNE DISEASES, for example) can also have disastrous consequences. Incidental observations that some noninfectious diseases, including inflammatory disorders, are improved by antibacterials have bolstered interest in the IMMUNOMODULATORY activity of antibacterial drugs.A better knowledge of the IMMUNE SYSTEM and its regulation, as well as technological advances, have facilitated such investigations.There are many possibilities for host-(microbe)-ABA interplay. Two clinically relevant effects of antibacterials are currently recognized, namely toxic and immunotoxic effects, and intracellular BIOACTIVITY. Other possibilities are modulation of bacterial virulence (leading to antibacterial synergy or a proinflammatory effect); ABA activation/inactivation by host cell activities; and modulation of cell functions or products by ABA (resulting in immunostimulation, immunodepression or antiinflammatory activity).These general aspects of ABA IMMUNOMODULATO-RY effects are reviewed in [4,6,9] and summarized here in Table 1 [9-16].Modulation (stimulation/inhibition) of host cell activities is the most widely investigated and most controversial area. Some ABA can either increase or decrease a given function in vitro, depending on the cell type, the technique used, and other variables such as the drug concentration and cell activation status.Effects observed in vitro may differ from those occurring ex vivo/in vivo,which result from the combined activities of the different players: the host and its cellular and humoral (redundant) effectors, the pathogen and its virulence mechanisms, and the physicochemical, pharmacokinetic (concentration, tissue distribution, metabolism) and antibacterial properties of the ABA in question. In vivo studies are the gold standard, but are subject to multiple pitfalls such as species differences in the composition and functions of the IMMUNE SYSTEM [17], as well as ethical problems and interindividual variability. This complexity of potential ABA interference with the IMMUNE SYSTEM helps to explain why the search for new therapeutic applications is so arduous. Nonetheless, major progress has been made in developing IMMUNOMODULATORY ABA, as described below (Part III). A simplified representation of the IMMUNOMODULATORY profile of ABA is given in Figure 1 (modified from [6], ...